|Systematic (IUPAC) name|
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9nM at CB1 and 23.2nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.
- Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
- Uchiyama, N.; Matsuda, S.; Wakana, D.; Kikura-Hanajiri, R.; Goda, Y. (2012). "New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products". Forensic Toxicology 31: 93. doi:10.1007/s11419-012-0171-4.
- Behonick, G; Shanks, K. G.; Firchau, D. J.; Mathur, G; Lynch, C. F.; Nashelsky, M; Jaskierny, D. J.; Meroueh, C (2014). "Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22". Journal of analytical toxicology 38: 559–62. PMID 24876364. doi:10.1093/jat/bku048.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.